These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37731733)

  • 1. Population pharmacokinetics of Amisulpride in Chinese patients with schizophrenia with external validation: the impact of renal function.
    Li A; Mak WY; Ruan T; Dong F; Zheng N; Gu M; Guo W; Zhang J; Cheng H; Ruan C; Shi Y; Zang Y; Zhu X; He Q; Xiang X; Wang G; Zhu X
    Front Pharmacol; 2023; 14():1215065. PubMed ID: 37731733
    [No Abstract]   [Full Text] [Related]  

  • 2. Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level.
    Huang S; Li L; Wang Z; Xiao T; Li X; Liu S; Zhang M; Lu H; Wen Y; Shang D
    Drug Des Devel Ther; 2021; 15():3903-3913. PubMed ID: 34548782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacokinetic analysis of amisulpride in adult Chinese patients with schizophrenia: Impact of creatinine clearance.
    Liu W; Zhou J; Cao M; Zhang F; Sun X
    Int J Clin Pharmacol Ther; 2023 Mar; ():. PubMed ID: 36871243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
    Fabre MA; Fuseau E; Ficheux H
    J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation.
    Liu XQ; Zhang YF; Ding HY; Yan MM; Jiao Z; Zhong MK; Ma CL
    Acta Pharmacol Sin; 2022 Oct; 43(10):2723-2734. PubMed ID: 35354961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants.
    Chen Y; Wu D; Dong M; Zhu Y; Lu J; Li X; Chen C; Li Z
    Eur J Clin Pharmacol; 2018 Jul; 74(7):921-930. PubMed ID: 29602981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal Teicoplanin Dosage Regimens in Critically Ill Patients: Population Pharmacokinetics and Dosing Simulations Based on Renal Function and Infection Type.
    Wang Y; Yao F; Chen S; Ouyang X; Lan J; Wu Z; Wang Y; Chen J; Wang X; Chen C
    Drug Des Devel Ther; 2023; 17():2259-2271. PubMed ID: 37546521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.
    Zhao W; Cella M; Della Pasqua O; Burger D; Jacqz-Aigrain E;
    Br J Clin Pharmacol; 2012 Apr; 73(4):641-50. PubMed ID: 21988586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new population pharmacokinetic model for vancomycin in patients with variable renal function: Therapeutic drug monitoring based on extended covariate model using CKD-EPI estimation.
    Kim DJ; Lee DH; Ahn S; Jung J; Kiem S; Kim SW; Shin JG
    J Clin Pharm Ther; 2019 Oct; 44(5):750-759. PubMed ID: 31228353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two Innovative Approaches to Optimize Vancomycin Dosing Using Estimated AUC after First Dose: Validation Using Data Generated from Population PK Model Coupled with Monte-Carlo Simulation and Comparison with the First-Order PK Equation Approach.
    Liu Q; Huang H; Xu B; Li D; Liu M; Shaik IH; Wu X
    Pharmaceutics; 2022 May; 14(5):. PubMed ID: 35631590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics and Dosing Regimen of Lithium in Chinese Patients With Bipolar Disorder.
    Jin ZB; Wu Z; Cui YF; Liu XP; Liang HB; You JY; Wang CY
    Front Pharmacol; 2022; 13():913935. PubMed ID: 35860024
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase 1 Renal Impairment Trial Results Supports Targeted Individualized Dosing of ELX-02 in Patients With Nephropathic Cystinosis.
    Haverty T; Wyatt DJ; Porter KM; Leubitz A; Banks K; Goodyer P; Hu MY
    J Clin Pharmacol; 2021 Jul; 61(7):923-931. PubMed ID: 33355924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study.
    Shekar K; Fraser JF; Taccone FS; Welch S; Wallis SC; Mullany DV; Lipman J; Roberts JA;
    Crit Care; 2014 Dec; 18(6):565. PubMed ID: 25636084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vancomycin population pharmacokinetics analysis in Chinese paediatric patients with varying degrees of renal function and ages: development of new practical dosing recommendations.
    Chen J; Huang X; Yu L; Li J; Yang R; Li L; Zhou J; Yao H; Bu S
    J Antimicrob Chemother; 2023 Aug; 78(8):2037-2051. PubMed ID: 37379498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment.
    Boinpally R; Alcorn H; Adams MH; Longstreth J; Edwards J
    Clin Drug Investig; 2013 Mar; 33(3):199-206. PubMed ID: 23417352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of Linezolid Dose Adjustment for Creatinine Clearance in Critically Ill Patients: A Multicenter, Prospective, Open-Label, Observational Study.
    Wang X; Wang Y; Yao F; Chen S; Hou Y; Zheng Z; Luo J; Qiu B; Li Z; Wang Y; Wu Z; Lan J; Chen C
    Drug Des Devel Ther; 2021; 15():2129-2141. PubMed ID: 34040351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function.
    Gijsen M; Elkayal O; Annaert P; Van Daele R; Meersseman P; Debaveye Y; Wauters J; Dreesen E; Spriet I
    Infect Drug Resist; 2022; 15():53-62. PubMed ID: 35035223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation Analysis.
    Xu H; Zhou W; Zhou D; Li J; Al-Huniti N
    J Clin Pharmacol; 2017 Mar; 57(3):336-344. PubMed ID: 27530649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetics and Hemorrhagic Risk Analysis of Rivaroxaban in Elderly Chinese Patients With Nonvalvular Atrial Fibrillation.
    Zhang D; Chen W; Qin W; Du W; Wang X; Zuo X; Li P
    J Clin Pharmacol; 2023 Jan; 63(1):66-76. PubMed ID: 36029108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus.
    Saito M; Kaibara A; Kadokura T; Toyoshima J; Yoshida S; Kazuta K; Ueyama E
    Br J Clin Pharmacol; 2019 Aug; 85(8):1808-1819. PubMed ID: 31026084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.